Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer
Open Access
- 11 August 2010
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 304 (6) , 657-663
Abstract
Bisphosphonates inhibit osteoclast-mediated bone resorption and are mainly used to prevent or treat osteoporosis, especially in postmenopausal women. Bisphosphonate use has increased dramatically in recent years in the United States and other Western populations,1,2 and bisphosphonates are now commonly prescribed in elderly women; eg, in 2005, approximately 10% of UK women older than 70 years received a bisphosphonate prescription.3Keywords
This publication has 18 references indexed in Scilit:
- More on Reports of Esophageal Cancer with Oral Bisphosphonate UseNew England Journal of Medicine, 2009
- Reports of Esophageal Cancer with Oral Bisphosphonate UseNew England Journal of Medicine, 2009
- Antitumor effects of bisphosphonates: Promising preclinical evidenceCancer Treatment Reviews, 2008
- Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005European Journal of Clinical Pharmacology, 2007
- Effect of the Women's Health Initiative on Osteoporosis Therapy and Expenditure in MedicaidJournal of Bone and Mineral Research, 2006
- Effect of clinical trial publicity on HRT prescribing in IrelandEuropean Journal of Clinical Pharmacology, 2006
- Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylationBJU International, 2004
- Calcium-channel blockers and risk of cancerThe Lancet, 1997
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.BMJ, 1991